Recently the Kidney Cancer Association held its International Kidney Cancer Symposium, where medical professionals and other industry members come together to share ideas and push for innovative research and treatments…
The COVID-19 vaccine was approved quickly by the FDA in an effort to fight the raging pandemic. Due to the rapid pace of these trials, a number of populations weren't…
Merck has just received FDA approval for their recently acquired drug Welireg. This HIF-2α blocker is indicated for von Hippel-Lindau disease (VHL). This rare disease gives affected individuals a higher…
A new pooled data analysis of the frontline treatments for metastatic renal cell carcinoma (mRCC) has just been completed. It demonstrated that there is a difference in overall survival for…
Renal cell carcinoma (RCC) is typically treated with single-agent tyrosine kinase inhibitors (TKIs). Now, this may be changing as research demonstrates the potential of the combination of TKIs and immunotherapy.…
Recently, the National Cancer Institute provided a $2.5M grant to support specialized medical research being performed at the Wake Forest Organoid Research Center (WFORCE). According to the press release,…
For nearly 130 years, pharmaceutical company Merck & Co ("Merck" or "MSD") has been working to develop unique therapeutic solutions for those with rare cancers and a variety of…
The American Society of Clinical Oncology will soon hold their Genitourinary Cancers Symposium (ASCO GU) from February 11 through 13, 2021. The symposium, held virtually during COVID-19, will feature…
Happy Friday! November 1 is International Acromegaly Day. For those unaware, Acromegaly is a rare condition characterized by the presence of an elevated level of growth hormone and typically effects…
Earlier this week, the FDA granted Priority Review status to use a combination of Opdivo-Cabometyx as a treatment for patients with renal cell carcinoma (RCC). According to Healio, Opdivo (nivolumab)…
According to a story from Targeted Oncology, an experimental combination therapy tested on patients with advanced clear cell renal cell carcinoma (ccRCC) appeared to show potential for efficacy in a…
This past week, Bristol Myers Squibb shared four-year data from the Phase 3 CheckMate-214 clinical trial. Ultimately, the trial sought to understand the safety, efficacy, and tolerability of Opdivo…
According to Ryan McDonald of Cure Today, the FDA recently granted Breakthrough Therapy Designation to MK-6482, an investigational HIF-2α inhibitor developed by Merck. The orally-administered drug, designed to treat…
According to a story from Medscape, a recent cohort study published in the journal Cancer has concluded that updates are needed to the staging classification currently in use for renal cell carcinoma…
"I thought it was a hernia." When George Benson experienced lower abdominal pain in 2009, at age 51, he wasn't concerned. He was a truck driver, artist, and family…
Phase III of the CheckMate -9ER trial has reached its primary endpoint of progression free survival in those with advanced or metastatic renal cell carcinoma. This study was evaluating CABOMETYX…
A recent Biospace article covers a news release from 4D Pharma in Leeds, England. 4D has announced the first worldwide clinical confirmation of a biotherapeutic product. MRx0518 has been combined…
No Cure, No Pay Emile Voest, an oncologist in the Netherlands, conceived the idea of a no cure, no pay model. After witnessing the exorbitant cost of drugs, some of…
According to a story from finanznachrichten.de, the biotherapeutics company 4D pharma has recently announced a research partnership with the MD Anderson Cancer Center at the University of Texas. The goal of…
Ipsen has just announced that they will be acquiring Clementia Pharmaceuticals. This merging of companies is exciting for the rare community because it will strengthen the resources, knowledge-base, and overall…
The treatment of metastatic renal cell carcinoma (RCC) has evolved over the last ten years and investigators now look towards combination therapies to improve response rates and durability for…
There is a high unmet need to find more effective treatments for liver cancer. Currently, treatment options for patients often only increase life expectancy by 3 to 4 months. An accidental…
According to an article from Global Banking & Financing Review, the California-based pharmaceutical company Exelixis, Inc. has announced the FDA's approval of their drug Cabometyx (cabozantinib) for patients previously diagnosed…
According to a story from BioPortfolio, the Bristol-Myers Squibb Company recently announced that the European Commission has recently approved the first combination treatment for renal cell carcinoma available in the…
According to a story from BioSpace, EUSA Pharma and AVEO Oncology recently announced the release of updated interim results from the second Phase of a Phase Ib/2 clinical trial which…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
